Logo
Neofound Whitening (5 x 3ml)

Neofound Whitening (5 x 3ml)

Neofound

Aesthetic Injectables
  • Marketed as a professional injectable skin booster / medical device manufactured by Love Cosmedical under EU medical device quality standards (e.g. ISO 13485) with CE marking (as listed by distributors).
  • Distributed through regulated professional aesthetic channels with batch traceability and professional Only access.
  • Use is restricted to qualified healthcare professionals in line with local regulatory, pharmacy and advertising requirements for injectable aesthetic treatments.
Bio-remodelling Skin Booster / Hyperpigmentation Mesotherapy

Description

Neofound Whitening (5 x 3ml) is an injectable hyperpigmentation treatment from the Neofound family, manufactured in Italy by Love Cosmedical. Formulated specifically to harmonise skin tone across all phototypes, it targets melasma, pregnancy mask and dark patches by modulating melanogenesis and addressing pigmentation at a cellular level. Based on a cocktail of tranexamic acid, N-acetylcysteine, amino acids (glycine–proline–arginine), niacinamide and a Neofound-style bio-remodelling base, it combines pigment-control activity with antioxidant, collagen-stimulating and hydrating effects. The result is brighter, more even, globally reconditioned skin on the face and body, with visible improvement in hyperpigmented areas after a short course of treatments.

Bnefits

  • Specifically designed to treat hyperpigmentation, melasma (pregnancy mask) and dark patches while simultaneously improving overall skin quality.
  • Formulation developed to harmonise and even skin tone for a wide variety of skin types and phototypes.
  • Uses tranexamic acid to help inhibit melanogenesis signalling pathways, targeting pigmentation at its root rather than only lightening the surface.
  • Contains N-acetylcysteine, a potent antioxidant that reduces oxidative stress and free radical damage associated with photoageing and pigment formation.
  • Amino acids (glycine–proline–arginine) support collagen synthesis, tissue repair and structural integrity for smoother, firmer skin.
  • Niacinamide (vitamin B3) provides additional antioxidant and brightening effects, helping to reduce dyschromia and improve barrier function.
  • Delivers a Neofound-like bio-remodelling effect (hydration, elasticity, texture improvement) while placing sharp focus on pigment correction.
  • Suitable for treating both facial and body hyperpigmentation; can be delivered by micro-injections or combined with microneedling for larger body areas.
  • Structured protocol (sessions every 14 days) allows predictable treatment planning and clear communication of expected course to patients.
  • Can be integrated into broader hyperpigmentation protocols alongside sun protection and other medical skincare for comprehensive results.

Indications

  • Injectable hyperpigmentation treatment for melasma (including pregnancy mask) and other forms of facial and body hyperpigmentation.
  • Dark patches and uneven tone due to sun damage, age spots and post-inflammatory hyperpigmentation, where injectable mesotherapy-style treatments are appropriate.
  • Patients seeking harmonisation of skin tone with concurrent improvement in texture, hydration and fine lines.
  • Use on face and body in areas up to at least 10 cm x 10 cm per millilitre, as guided by treatment protocols.
  • Intended exclusively for professional use by qualified medical/aesthetic practitioners trained in intradermal injection and mesotherapy techniques.

Composition

  • Tranexamic Acid – 0.1% concentration; antifibrinolytic molecule used here to help modulate melanogenesis and reduce hyperpigmentation.
  • N-Acetylcysteine (Acetylcysteine / N-acetyl-L-cysteine) – antioxidant derivative of L-cysteine that reduces oxidative stress and supports cellular protection.
  • Glycine–Proline–Arginine – amino acid complex supporting collagen synthesis, dermal matrix integrity and positive biological effects on skin renewal.
  • Niacinamide (Vit PP / Vitamin B3) – antioxidant and brightening cofactor precursor of NAD(P)/NAD(P)H, improving barrier function and tone.
  • Hyaluronic acid / Sodium hyaluronate (as part of the Neofound bio-remodelling base) – provides hydration, tissue support and contributes to lifting and elasticity.
  • Additional excipients – sterile injectable solution base, buffering and stabilising agents appropriate for intradermal/mesotherapy administration (full excipient list as per IFU).

Formulation

  • Sterile injectable skin booster / mesotherapy solution for intradermal or very superficial injection.
  • Pack size: 5 x 3ml glass vials (total 15ml) per box.
  • Each vial contains 3ml of Neofound Whitening solution containing tranexamic acid 0.1% plus N-acetylcysteine, amino acids and niacinamide in a Neofound-style base.
  • Intended for use with fine needles (e.g. 30G) for micro-injections in the papillary/reticular dermis, or via microneedling pens for larger body areas as per professional protocol.
  • Designed as part of a multi-session course targeting pigmentation with concomitant bio-remodelling effects.
  • Medical device / skin booster for professional aesthetic use; not a traditional volumising dermal filler.

Packaging

  • Outer branded carton labelled "Neofound Whitening" containing 5 sterile 3ml glass vials.
  • Each vial sealed with rubber stopper and aluminium/plastic flip-off cap suitable for aseptic withdrawal.
  • Carton and vials display product name, volume (3ml), batch/lot number, expiry date (e.g. *Expires 28/02/26* on relevant batches), manufacturer (Love Cosmedical) and regulatory markings such as CE mark.
  • Supplied through professional aesthetic distributors (e.g. Teleta) with tamper-evident packaging and clear categorisation under Bio-Remodelling / Skin Boosters.

Usage

  • For professional use only by suitably trained and qualified medical/aesthetic practitioners.
  • Conduct a full medical and aesthetic consultation, including history, type and pattern of hyperpigmentation, skin phototype and expectations.
  • Cleanse and disinfect the treatment area thoroughly; topical anaesthetic may be used if appropriate.
  • Withdraw Neofound Whitening aseptically from the vial into a sterile syringe using a fine needle, following standard aseptic technique.
  • Recommended schedule: one session every 14 days (approximately fortnightly).
  • Typical course: 3 sessions are recommended initially, with adjustments based on professional opinion, treatment goals and observed results.
  • Dosage guideline: 1ml of product per session covers an area of approximately 10 cm x 10 cm; multiple millilitres can be used for larger indications as clinically appropriate.
  • Injection technique: intradermal micro-injections or mesotherapy-style papules over the affected hyperpigmented area and periphery, using the same injection method as original Neofound meso vials.
  • For larger body areas impacted by hyperpigmentation, microneedling pens may be used to deliver the product in accordance with device and product guidance.
  • After treatment, apply soothing or barrier-support products if needed and advise strict photoprotection (broad-spectrum sunscreen, protective clothing) and avoidance of aggressive topical agents in the immediate post-treatment period.
  • Monitor patient response over the course of treatments; consider maintenance or combination protocols (e.g. with Neofound injections, peels, topical depigmenting agents) according to clinical judgment and guidelines.

Contraindications

  • Known hypersensitivity or allergy to tranexamic acid, N-acetylcysteine, niacinamide, amino acids in the formulation, hyaluronic acid or any other component of the solution.
  • Active infection, inflammation, dermatitis, or open lesions at the intended treatment site.
  • History of severe allergic reactions or anaphylaxis to injectable skin boosters or mesotherapy products.
  • Pregnancy and breastfeeding are generally considered contraindications for elective aesthetic mesotherapy procedures, including Neofound Whitening, unless specifically justified and approved by a qualified physician.
  • Uncontrolled systemic illness, significant autoimmune disease or immunosuppression, unless carefully assessed and deemed appropriate by the treating clinician.
  • Bleeding disorders or current use of strong anticoagulant/antiplatelet therapy that substantially increases bleeding/bruising risk, unless managed and approved by the practitioner.
  • History of severe keloid or hypertrophic scarring in the proposed treatment area.
  • Any patient in whom the treating professional, based on clinical judgment and local guidelines, considers the treatment unsafe or unsuitable.

Adverse Effects

  • Common transient injection-site reactions: redness (erythema), swelling, tenderness, small papules, mild pain or stinging, pinpoint bleeding and bruising.
  • Short-term oedema or textural irregularities in treated areas, usually resolving within a few days.
  • Post-inflammatory hyperpigmentation (especially in darker phototypes) if aftercare and photoprotection are inadequate; risk can be mitigated with strict SPF use and gentle skincare.
  • Less common: local inflammatory reactions, prolonged erythema, persistent nodules or induration requiring clinical assessment and possibly additional management.
  • Rare: infection at injection sites if aseptic technique is not rigorously followed, presenting with pain, warmth, increasing redness or purulent discharge, requiring medical treatment.
  • Very rare but serious risks associated with injectable procedures, such as vascular occlusion or tissue necrosis if product is inadvertently injected intravascularly or compromises blood flow; requires immediate recognition and emergency management by experienced practitioners.

Storage Conditions

  • Store in a cool, dry place at controlled room temperature within the range recommended by the manufacturer (commonly around 2–25°C).
  • Do not freeze; protect from excessive heat, direct sunlight and moisture.
  • Keep vials in their original outer carton to protect from light and maintain identification and traceability.
  • Do not use after the expiry date printed on the vial and outer packaging (e.g. *Expires 28/02/26* for relevant batches).
  • Use each vial for a single patient; once opened, use immediately and discard any remaining product. Do not attempt to re-sterilise or reuse.
  • Store in a secure area accessible only to authorised clinic staff, in accordance with local regulations for medical/aesthetic injectables.

Duration

Protocol typically consists of 3 sessions performed every 14 days (approximately over 4\u20136 weeks), with the option to adapt the number and frequency of sessions based on professional assessment and treatment goals. Maintenance or repeat courses may be scheduled according to recurrence or persistence of hyperpigmentation.

Onset

Some patients may notice visible brightening and reduction of hyperpigmented areas after the first session, with progressive improvement through the 2nd and 3rd sessions. More significant and stable tone harmonisation generally becomes apparent over several weeks following completion of the initial course.

Browse more Aesthetic Injectables

Top Treatments

Top Cities in the UK